Tongling Bionic Wins Gold Medal at Geneva International Exhibition of Inventions

The awards ceremony for the 51st International Exhibition of Inventions of Geneva recently concluded successfully in Geneva, Switzerland. This year's exhibition brought together over a thousand cutting-edge inventions from 35 countries and regions. Anhui Tongling Bionic Technology Co., Ltd., in collaboration with Fujian Medical University, Changchun University of Chinese Medicine, and Sun Yat-sen University, submitted the "Portable Home-Based Cardiovascular and Cerebrovascular Rehabilitation Device Based on Artificial Intelligence." Leveraging groundbreaking technological breakthroughs and accessible medical value, the project won the Jury's Gold Medal.

Concurrently, the project was independently awarded the "Excellence in Research and Innovation Award" by the National Institute for Research and Development in Microtechnologies (IMT) of Romania, making it a rare Chinese original medical AI technology at this year's exhibition to achieve the dual honors of "Gold Medal + Special Grand Prize," highlighting the global innovation strength of China's high-end medical devices.

Cardiovascular and cerebrovascular diseases are the leading chronic threat to human life and health worldwide. For a long time, Enhanced External Counterpulsation (EECP), a clinically proven non-invasive circulatory assistance technology, has been largely confined to top-tier hospital settings due to bulky equipment, high noise levels, complex operation, and lack of intelligence. This has created a medical dilemma of "effective in-hospital, disconnected out-of-hospital," leading to difficulties in patient follow-up visits, long queues, and unmet needs for rehabilitation in community and home settings. Hundreds of millions of families coping with chronic diseases lack continuous, professional cardiovascular health support.

Tongling Bionic has been deeply cultivating the field of bionic medicine for many years. Leveraging a national-level postdoctoral research workstation, the Anhui Provincial Key Laboratory of Bionic Medicine, and collaborations with Sun Yat-sen University and other institutions, supported by research from a national key R&D program, the company has focused on addressing the key pain points of cardiovascular chronic disease rehabilitation to achieve core technological breakthroughs. This award-winning "Portable Home-Based Cardiovascular and Cerebrovascular Rehabilitation Device" breaks the constraints of traditional equipment form factors, achieving revolutionary upgrades across four dimensions: miniaturization, noise reduction, intelligence, and home-use orientation. The device's size is significantly reduced, its operational noise is markedly lowered, and it features a self-developed AI intelligent algorithm with a highly simplified operational process. Patients can now undergo professional-grade cardiovascular rehabilitation treatment at home without the need for a specialist technician, truly closing the loop from "in-hospital treatment" to "out-of-hospital rehabilitation."

These two major international awards represent authoritative recognition from the global science and innovation community of Tongling Bionic's technological strength, clinical value, and societal impact:

Gold Medal at the Geneva International Exhibition of Inventions: Evaluated by an international jury for its level of innovation, practical value, and commercialization potential, it is often regarded as a "Nobel Prize barometer" in the global innovation community, representing the highest affirmation of the project's robust innovation and real-world applicability.

IMT Excellence in Research and Innovation Award (Romania): Independently adjudicated by a leading European national-level microtechnology research institution, this award specifically recognizes the project's pioneering innovative contributions in the field of medical-engineering convergence and bionic medicine.

The combination of these two international awards signifies that Tongling Bionic's original bionic medical technology has officially entered the first echelon of global high-end medical device innovation, confirming the increasing technological influence of Chinese companies in the field of chronic disease rehabilitation.

Leveraging its core technological advantages, the device achieves full-scenario coverage, completely breaking down the barriers of top-tier hospital settings:

Home Rehabilitation: Patients with chronic cardiovascular diseases can receive the same level of professional counterpulsation rehabilitation as in a top-tier hospital from the comfort of their homes, eliminating issues related to queuing and bed shortages.

Elderly Care Institutions: Provides continuous cardiovascular health maintenance for the elderly, filling the gap in professional rehabilitation within elder care settings.

Primary Clinics: Assists community and county-level medical institutions in offering cardiovascular chronic disease rehabilitation services, improving the tiered diagnosis and treatment system.

Remote Areas: Brings advanced rehabilitation therapies to regions with weak medical resources, enabling accessible healthcare to transcend geographical limitations.

Currently, this award-winning device is entering the preparatory stage for market launch. Tongling Bionic is actively engaging with national top-tier hospitals, chain rehabilitation institutions, elderly care service groups, and regional distributors to advance the full-chain deployment of product registration, mass production, and channel development. It will soon be officially launched, providing millions of families dealing with cardiovascular chronic diseases with an accessible, convenient, and professional rehabilitation solution.

As a pioneer of the bionic medicine theoretical system in China, Tongling Bionic remains committed to its original aspiration: "Using the pinnacle of technology to achieve the beauty of life." In the future, the company will continue to deeply cultivate the fields of bionic medicine and high-end cardiovascular medical devices. Leveraging national-level research platforms and its industry-university-research innovation system, it will tackle core technologies such as pVAD and IABP, accelerate its listing process on the STAR Market, and break overseas monopolies with original Chinese technology. Simultaneously, the company will persistently promote the accessibility of medical technology, bringing professional cardiovascular health care to every family and benefiting every life, safeguarding the heart health of people globally with China's bionic technology.